Search results
Legend Biotech (NASDAQ:LEGN) Stock Rating Reaffirmed by HC Wainwright
ETF DAILY NEWS· 5 days agoLegend Biotech (NASDAQ:LEGN – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research ...
Brokerages Set Whitbread plc (LON:WTB) Target Price at GBX 4,192.50
ETF DAILY NEWS· 5 hours agoWhitbread plc (LON:WTB – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat ...
HC Wainwright Reaffirms Buy Rating for Krystal Biotech (NASDAQ:KRYS)
ETF DAILY NEWS· 5 days agoHC Wainwright reaffirmed their buy rating on shares of Krystal Biotech (NASDAQ:KRYS – Free Report) in a research report released on Monday morning, Benzinga ...
Why Soleno Therapeutics Stock Is Skyrocketing Today
Motley Fool via Yahoo Finance· 16 hours agoIs Soleno Therapeutics stock a buy? There's no guarantee Soleno will win FDA approval for diazoxide choline, but its chances look pretty good at this...
Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades.
Motley Fool via Yahoo Finance· 3 days agoI'm most excited, though, about the rest of Vertex's pipeline. The biotech expects to soon file for...
Nasdaq Bull Market: Here's the Best Investing Move You Can Make Right Now
Motley Fool via Yahoo Finance· 22 hours agoAnd, most importantly, choose companies you want to hold onto for a number of years. This way, you...
Where Will Iovance Biotherapeutics Stock Be in 5 Years?
Motley Fool via Yahoo Finance· 2 days agoAt a hefty $3 billion valuation, there's already a bit too much optimism priced into the stock right...
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
InvestorPlace· 5 days agoIf you have a high tolerance for volatility then the biotech sector might be for you. Biotech stocks...
Sigma Planning Corp Has $443,000 Stock Holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI)
ETF DAILY NEWS· 4 days agoSigma Planning Corp cut its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 51.7% during the fourth quarter, according to its most recent disclosure with the ...
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
Motley Fool via Yahoo Finance· 2 days agoAs such, this biotech stock is a highly aggressive growth play best suited for individuals with a long-term horizon and a high tolerance for volatility.